Christos Kapogiannis
Pulmonary Disease · North Dartmouth, MANPI 1215999495
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,231 of the $65,257 with a category attached, or 75.4%. Mylan Specialty L.p. accounts for 80.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $31,388 and has fallen 55.5% since, to $13,971 in 2022. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 304 payments — averaging $214.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$52K
- AstraZeneca$10K
- Sunovion Pharmaceuticals Inc.$2K
- Boehringer Ingelheim$198
- GSK$152
- E.r. Squibb & Sons, L.L.C.$110
- plus $428 from 8 others
What the payments were for
- Consulting fees$6,58210%
- Speaking & faculty fees$49,23175%
- Travel & lodging$2,7354%
- Food & beverage$6,62410%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 109 | $52,435 |
| AstraZeneca | 149 | $10,109 |
| Sunovion Pharmaceuticals Inc. | 3 | $1,826 |
| Boehringer Ingelheim | 5 | $198 |
| GSK | 10 | $152 |
| E.r. Squibb & Sons, L.L.C. | 5 | $110 |
| Genentech USA, Inc. | 6 | $94 |
| Electromed, Inc. | 8 | $90 |
| Resmed Corp | 1 | $86 |
| Pfizer | 4 | $72 |
| Sanofi | 1 | $36 |
| Philips North America LLC | 1 | $19 |
| Novartis | 1 | $19 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$51,001
- TEZSPIRE$7,487
- LONHALA MAGNAIR$1,700
- BREZTRI$440
- FASENRA$440
- TUDORZA PRESSAIR$210
How this compares
$65,257 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in North Dartmouth
- Curtis MelloNorth Dartmouth$99K
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
- Nicholas HillBoston$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.